| |
 |
Editorial [Hot Topic:Non-Receptor Tyrosine Kinases as Molecular Targets for Patient Tailored Cancer Therapy (Guest Editors: F.M. Uckun, A. Vassilev and H. Tibbles)]
 |
| |
|
pp.593-593 (1) Authors: Fatih M. Uckun, Alexei Vassilev, Heather Tibbles |
| |
|
|
| |
|
Oncogenic Fusion Tyrosine Kinases as Molecular Targets for Anti-Cancer Therapy
|
| |
|
pp.594-611 (18) Authors: Rosalind H. Gunby, Elisa Sala, Carmen J. Tartari, Miriam Puttini, Carlo Gambacorti-Passerini, Luca Mologni |
| |
|
|
| |
|
Targeting JAK3 Tyrosine Kinase-Linked Signal Transduction Pathways with Rationally-Designed Inhibitors
|
| |
|
pp.612-623 (12) Authors: Fatih M. Uckun, Alexei Vassilev, Ilker Dibirdik, Heather Tibbles |
| |
|
|
| |
|
Bruton's Tyrosine Kinase as a New Therapeutic Target
|
| |
|
pp.624-632 (9) Authors: Fatih M. Uckun, Heather E. Tibbles, Alexei O. Vassilev |
| |
|
|
| |
|
Non-Receptor Tyrosine Kinase Inhibitors in Lung Cancer
|
| |
|
pp.633-642 (10) Authors: Olwen Hahn, Ravi Salgia |
| |
|
|
| |
|
Jak2 Tyrosine Kinase and Cancer: How Good Cells Get HiJAKed
|
| |
|
pp.643-650 (8) Authors: Michael D. Godeny, Peter P. Sayeski |
| |
|
|
| |
|
Src Family Nonreceptor Tyrosine Kinases as Molecular Targets for Cancer Therapy
|
| |
|
pp.651-659 (9) Authors: Faye M. Johnson, Gary E. Gallick |
| |
|
|
| |
|
Synthetic Src-Kinase Domain Inhibitors and Their Structural Requirements
|
| |
|
pp.660-680 (21) Authors: Silvia Schenone, Fabrizio Manetti, Maurizio Botta |
| |
|
|
| |
|
Role of Focal Adhesion Kinase in Human Cancer: A Potential Target for Drug Discovery
|
| |
|
pp.681-684 (4) Authors: Edward Kyu-Ho Han, Thomas McGonigal |
| |
|
|
| |
|
Synthesis and Structure-Activity Relationships of Potent Antitumor Active Quinoline and Naphthyridine Derivatives
|
| |
|
pp.685-709 (25) Authors: Sanjay K. Srivastava, Amrita Jha, Shiv K. Agarwal, Rama Mukherjee, Anand C. Burman |
| |
|
|
